Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)

NCT03460769 · View on ClinicalTrials.gov ↗

Study Summary

The Coordinating and Data Management Center (CDMC) at MD Anderson Cancer will be responsible for the coordination and data management for the Evaluation of a mixed meal test for Diagnosis and characterization of Type 3c diabetes mellitus secondary to pancreatic cancer and chronic pancreatitis (DETECT), which is part of the NIH U01 funded Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC). Similar to all studies that will be coordinated and managed by the CDMC, no patient enrollment will occur at MDACC. All patient recruitment will occur at external sites that are a part of the CPDPC, which are listed in the appended DETECT protocol. The data management systems, auditing, and monitoring effort are supported by the CDMC.

Interventions

  • OTHER Data Management and Monitoring

Study Locations (10)

California

  • Cedars-Sinai Medical Center — Los Angeles
  • Stanford University — Stanford

Minnesota

  • University of Minnesota — Minneapolis
  • Mayo Clinic — Rochester

Texas

  • Baylor College of Medicine — Houston
  • University of Texas MD Anderson Cancer Center — Houston

Florida

  • University of Florida — Gainesville

Indiana

  • Indiana University — Carmel

Ohio

  • Ohio State University — Columbus

Pennsylvania

  • University of Pittsburgh Medical Center — Pittsburgh

Trial Details

FieldValue
Enrollment Target 775 participants
Start Date 2021-04-01
Est. Completion 2027-06-30

Sponsor

M.D. Anderson Cancer Center

2,992 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03460769

The ClinicalTrials.gov registry entry for NCT03460769 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 775 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,992 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 3 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention — of which Data Management and Monitoring is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT03460769 reports 10 study locations spanning 7 distinct geographic areas — top geographies include California, Minnesota, Texas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT03460769 about?

NCT03460769 is a clinical study titled "Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)". The Coordinating and Data Management Center (CDMC) at MD Anderson Cancer will be responsible for the coordination and data management for the Evaluation of a mixed meal test for Diagnosis and characterization of Type 3c diabetes mellitus secondary to pancreatic cancer and chronic pancreatitis (DETEC...

What is the current status of trial NCT03460769?

This trial is currently recruiting. The enrollment target is 775 participants. The study started on 2021-04-01. Estimated completion is 2027-06-30.

What conditions does trial NCT03460769 study?

This clinical trial studies the following conditions: Pancreatic Cancer, Chronic Pancreatitis, Diabetes Mellitus Type 3c. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT03460769?

The interventions under investigation include: Data Management and Monitoring (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT03460769?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,992 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT03460769 being conducted?

This trial has 10 study locations across California, Florida, Indiana, Minnesota, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial